Clinical Trials
98 trialsNCT07146919 2026-04-23
ANGELICA
Centre Leon Berard
Phase 1/2 Withdrawn
NCT07060365 2026-04-03
A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer
AstraZeneca
Phase 1/2 Withdrawn
NCT05512260 2026-02-11
BESTa
Karolinska Institutet
Phase NA Withdrawn
NCT07226102 2026-02-04
Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic or Breast Cancer
City of Hope Medical Center
Phase NA Withdrawn
NCT05672095 2025-05-23
Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer
City of Hope Medical Center
Phase 1/2 Withdrawn
NCT02756130 2025-05-13
Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC)
Jonsson Comprehensive Cancer Center
Phase 1/2 Withdrawn
NCT05126342 2025-04-06
Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi
AGO Research GmbH
Phase 2 Withdrawn
NCT05714306 2025-03-05
CHUV-OVACURE
Centre Hospitalier Universitaire Vaudois
Phase 1/2 Withdrawn
NCT03197584 2025-02-21
QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT03632798 2025-02-12
ACSCO
Cordgenics, LLC
Phase 3 Withdrawn
NCT06120972 2025-02-12
Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency
University of Pittsburgh
Phase 2 Withdrawn
NCT06681870 2025-01-15
A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors
Astellas Pharma Inc
Phase 1 Withdrawn
NCT05145569 2025-01-01
Antitumor Activity of Neoadjuvant Chemotherapy with or Without HCW9218 in Metastatic Advanced Stage Ovarian Cancer
University of Pittsburgh
Phase 2 Withdrawn
NCT06161493 2024-10-15
ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors
University of Pittsburgh
Phase 1 Withdrawn
NCT06216561 2024-08-20
Intraperitoneal LSTA1 in CRS-HIPEC
University of California, San Diego
Phase 1 Withdrawn
NCT04542603 2024-04-25
Neuroinflammation and Age-associated Brain Pathology: Two Potential Mechanisms of Cognitive Impairment in Ovarian Cancer
University of Alabama at Birmingham
Phase 1 Withdrawn
NCT06284226 2024-04-16
CCT-ANK-11
Beijing Kejing Biotechnology Co., Ltd.
Phase EARLY_PHASE1 Withdrawn
NCT04102436 2024-03-12
Non-Viral TCR Gene Therapy
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT05238831 2024-01-23
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn
NCT05465590 2023-12-21
A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer
Mainline Biosciences, Inc.
Phase EARLY_PHASE1 Withdrawn
NCT03735589 2023-11-22
Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Roswell Park Cancer Institute
Phase 1/2 Withdrawn
NCT04602117 2023-11-18
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
QuantumLeap Healthcare Collaborative
Phase 1 Withdrawn
NCT05905341 2023-11-08
Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.
Pfizer
Phase 1 Withdrawn
NCT05201001 2023-09-11
APX005M
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase 2 Withdrawn
NCT05431582 2023-06-15
Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT04149145 2023-06-07
PARP
University of Alabama at Birmingham
Phase 1 Withdrawn
NCT05368506 2023-05-06
ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn
NCT04368130 2022-10-14
SIGNAL
Dana-Farber Cancer Institute
Phase NA Withdrawn
NCT02117817 2022-07-28
Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer
Rutgers, The State University of New Jersey
Phase 1 Withdrawn
NCT02201381 2022-07-18
METRICS
Health Clinics Limited
Phase 3 Withdrawn
NCT04941378 2022-06-27
OTL38 Injection (OTL38) for Intra-Operative Imaging of Folate Receptor Positive Ovarian Cancer
Abramson Cancer Center at Penn Medicine
Phase 1 Withdrawn
NCT04795596 2022-04-15
Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers
Menoufia University
Phase 2/3 Withdrawn
NCT03905902 2021-12-23
VITALIA
Sotio Biotech Inc.
Phase 3 Withdrawn
NCT04826029 2021-12-10
QUALOV
Assistance Publique - Hôpitaux de Paris
Phase NA Withdrawn
NCT03400306 2021-12-08
A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer
AbbVie
Phase 1 Withdrawn
NCT03634150 2021-10-26
Safety and Efficacy of IV Nerofeâ„¢ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer
Immune System Key Ltd
Phase 1/2 Withdrawn
NCT03933761 2021-08-10
PRECISE
Australia New Zealand Gynaecological Oncology Group
Phase 2 Withdrawn
NCT03806049 2021-07-15
Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase 3 Withdrawn
NCT04498520 2021-05-18
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer
University of California, San Francisco
Phase 1 Withdrawn
NCT04464967 2021-05-12
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
NKGen Biotech, Inc.
Phase 1/2 Withdrawn
NCT04239014 2021-03-10
DUETTE
AstraZeneca
Phase 2 Withdrawn
NCT01097239 2020-11-20
Examining the Role of Transrectal High Intensity Focused Ultrasound (HIFU) in Rectal Pelvic Cancer
Imperial College London
Phase 1/2 Withdrawn
NCT04561817 2020-10-06
To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer
Icahn School of Medicine at Mount Sinai
Phase 2 Withdrawn
NCT00753740 2020-06-12
Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.
Lumos Pharma
Phase 2 Withdrawn
NCT02713984 2020-03-19
A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
Southwest Hospital, China
Phase 1/2 Withdrawn
NCT03644459 2020-03-11
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101
Lynkcell Inc.
Phase 1 Withdrawn
NCT00693342 2020-02-24
Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission
GOG Foundation
Phase 3 Withdrawn
NCT01766622 2019-12-04
18F-CP18 Imaging Studies for Cancer Treatment With Birinapant
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT03281681 2019-10-18
REPROVe
Kintara Therapeutics, Inc.
Phase 1/2 Withdrawn
NCT02948101 2019-03-12
PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn